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Abstract
It is now widely recognized that robustness is an inherent property of biological systems [1,2,3]. The contribution of close
sequence homologs to genetic robustness against null mutations has been previously demonstrated in simple organisms
[4,5]. In this paper we investigate in detail the contribution of gene duplicates to back-up against deleterious human
mutations. Our analysis demonstrates that the functional compensation by close homologs may play an important role in
human genetic disease. Genes with a 90% sequence identity homolog are about 3 times less likely to harbor known disease
mutations compared to genes with remote homologs. Moreover, close duplicates affect the phenotypic consequences of
deleterious mutations by making a decrease in life expectancy significantly less likely. We also demonstrate that similarity of
expression profiles across tissues significantly increases the likelihood of functional compensation by homologs.
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Introduction
The ability of an organism to survive in various environmental
conditions indicates robustness to external perturbations. On the
other hand, relative insensitivity to harmful genetic mutations
represents genetic robustness. Several large scale gene deletion
studies demonstrated that organisms exhibit a significant degree of
genetic robustness against null mutations [6]. Although these
studies have an important caveat that genes without a detectable
phenotype may be essential under different growth conditions
[7,8], it is clear that genetic robustness is widespread in biological
systems [3].
Two distinct mechanisms of genetic robustness have been
extensively discussed. Alternative signaling or parallel metabolic
pathways illustrate network contributions to genetic robustness [9].
In contrast, a partial functional overlap between sequence paralogs
represents the contribution of gene duplicates. The study by Gu et
al. [4] demonstrated a significant contribution to functional
compensation by duplicate yeast genes. A similar pattern of the
functional compensation was also observed in C. elegans [5]. The
mechanism of genetic robustness by duplicates was recently
investigated by Kafri et al. [10], who showed that null deletions in
yeast are often compensated by over-expression of sequence
homologs.
The role and magnitude of the paralog contribution to
robustness against deleterious human mutations are not currently
well understood. While the study by Lopez-Bigas et al. [11]
suggested a contribution by highly conserved paralogs, Yue et al.
[12] showed recently that disease and all genes have an equal
fraction of paralogs. In the present work, we demonstrate the
importance of considering the sequence similarity between
paralogs for understanding the likelihood and magnitude of
functional compensation. We also explore the effects of mRNA co-
expression between duplicates on the observed functional back-up.
Understanding the mechanisms of genetic robustness will be
important for identification and prioritization of medically
important human mutations.
Results/Discussion
Disease and all gene sets
We investigated the functional compensation by duplicates
using three curated collections of human disease genes. Although
we currently do not know the total number of disease genes, more
than a thousand genes with known mutations affecting human
health have been identified [13]. First, we used the collection of
1003 Swiss-Prot [14] human genes with non-synonymous disease
mutations annotated in the OMIM database [13]. Second, we
investigated the collection of 1609 human genes from the OMIM
Morbid Map annotated to be involved in disease, but not as
susceptibility or non-disease. Our third disease gene set, obtained
from the study by Jimenez-Sanchez et al. [15], included a curated
collection of 881 human genes and the associated disease
phenotypes such as the age of onset and reduction in life
expectancy. The considered disease gene sets significantly overlap,
i.e. 636 genes are present in all three sets (see Figure S1,
Supporting Information).
Without a collection of human genes which are certainly non-
disease, we used several large collections of all human genes (all
gene sets). We primarily used the comprehensive collection of
20,262 human genes from the Ensembl build 35 [16]. As a
representative set of well-characterized human genes, we also
considered the collection of 12211 human genes from the Swiss-
Prot database [14].
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To understand the role of gene duplicates in robustness against
deleterious human mutations we searched for homologs of the
disease and all human genes using protein BLASTP [17] (see
Methods). Briefly, for each query sequence its closest human
paralog was identified as the non-self hit which can be aligned over
more than 80% of the length of both sequences. The sequence hits
with an E-value larger than 0.001 were not considered (results are
qualitatively insensitive to the gene set used or the cutoffs and
parameters applied in the similarity searches, see Table S1–S3,
Supporting Information). For the human genes with identified
paralogs (475 in the disease gene set and 8257 in the all-gene set),
the distributions of amino acid sequence identities of the closest
homologs are significantly different for disease and all-gene sets
(see Figure S2, Supporting Information). The average identity of
the closest homolog is 52.9% for disease genes and 58.3% for all
genes (non-parametric Wilcoxon’s test P=1.6*10
27). The ob-
served difference cannot be explained simply by the existence of
several large protein families with a small number of known
disease genes; after removing sequences with more than one
paralog in the human genome, the average identity of the closest
homolog is 50.0% for disease genes and 54.3% for all genes
(P=2*10
22). Neither can the difference arise due to difficulties in
disambiguating allelic variants from close sequence differences in
copy number variable genes [18,19]. After excluding genes with
highly similar paralogs of sequence identity greater than 90%, the
average identity of the closest paralog is 51.4% for disease genes
and 54.4% for all genes (P=7*10
24).
In Figure 1 we show the conditional probability that a human
gene will harbor a disease mutation given the amino acid sequence
identity of its closest homolog. To calculate the conditional
probability (see Methods) we assume that, although the total
number of human disease genes is not known, the currently
available collection of disease genes is unbiased towards sequence
identities of the closest homologs. Figure 1 demonstrates that genes
with at least 90% sequence identity to their closest homologs are
three times less likely to harbor disease mutations compared to
genes with remote paralogs. No correlation was observed between
the number of disease mutations in a gene (Spearman’s rank
correlation rS=20.025, P=0.6) or gene density of disease
mutations (rS=20.036, P=0.4) and the sequence identity of the
closest homolog. This suggests that the number of disease
mutations identified in genes may be determined primarily by
experimental, mutational, or gene history biases [20], and not
affected by the possibility of functional compensation. Similarly,
no correlation between deleterious variability and evolutionary
distance to murine orthologs was observed in the study by Sunyaev
et al. [21].
If close sequence homologs provide functional back-up against
medically damaging mutations, it is likely that they also contribute
to relaxation of constraints against deleterious human polymor-
phisms. As was demonstrated by Lynch et al. [22], most duplicated
genes experience a brief period of relaxed selection after
duplication. The functional constraints on human genes can be
estimated through the normalized ratio of non-synonymous to
synonymous single nucleotide polymorphisms (SNPs) per site (Ka/
Ks) [17,23]. A small value of the Ka/Ks ratio suggests a higher
constraint on a gene, i.e. a smaller fraction of observed non-
synonymous polymorphisms. Figure 2 shows the relationship
between the average Ka/Ks ratio and sequence identity to the
closest homolog (shown separately for all and validated SNPs from
the dbSNP database [24]). The Ka/Ks ratio of the validated SNPs
is about two times higher for genes with a 90% sequence identity
homolog compared to genes with remote homologs.
While there are many examples of homologous iso-enzymes
providing functional compensation [7,25], this mechanism is less
established for other functional classes. To understand the
significance of the duplicate compensation among various
functional categories we (applied the approach described in the
previous section and) compared sequence identities of closest
paralogs for disease genes and all human genes in the 53 ‘‘GO
slim’’ functional classes. Using a false discovery rate of 5%, we
found that, in additional to metabolism, the functional category
‘‘response to stimulus’’ showed evidence of statistically significant
compensation by duplicates (see Table 1 and Table S4,
Supporting Information); the ‘‘response to stimulus’’ category
contains cytokines, receptors, protein kinases and other proteins
involved in signal transduction. Consequently, functional com-
pensation by duplicates is not limited to metabolism and is also
significant among other important functional classes.
The observed paucity of close homologs for known disease
genes could be a consequence of their faster evolution in
comparison with all human genes. To investigate this possibility
we analyzed Ka and Ka/Ks values calculated using PAML [26]
for all 13055 one-to-one human-mouse orthologous pairs from the
Ensembl database [27]. Both Ka and Ka/Ks measures for known
disease genes are significantly lower than those of all-gene set
(mean/median Ka: disease 0.0729/0.0833, all 0.0851/0.0971,
P=4*10
22; mean/median Ka/Ks: disease 0.119/0.105, all
0.137/0.113, P=1*10
22.). These findings are in agreement with
the study by Kondrashov et al. [28] who considered 1273 disease
genes and 16580 other human genes. Although the earlier study
by Smith and Eyre-Walker [29] reported the opposite pattern (a
higher Ka/Ks ratio for disease genes), their results were based on
significantly smaller gene sets (387 disease and 2024 non-disease
genes). Consequently, it is unlikely that the elevated sequence
similarity between paralogs of non-disease genes is related to their
slower rate of evolution.
Recently, He et al. demonstrated a lower duplicability of
‘‘important’’ yeast genes (essential genes and genes with knockout
phenotypes) [30]. To explore the possibility that lower duplic-
ability of disease genes affects our results we followed the approach
by He et al. [30]. Based on the Ensembl database [27] we identified
singleton human genes (genes without duplicates in the human
genome, see Methods) with mouse, chicken, and zebrafish
orthologs. We then looked at whether the orthologs of singleton
Author Summary
Genetic robustness is the ability of an organism to buffer
deleterious genetic mutations. It has been previously
demonstrated that the functional compensation by
duplicates plays an important role in protection against
gene deletions in model organisms. Close duplicates often
share similar functions, and loss of one paralog may be
buffered by others. In the present work we specifically
investigate the contribution of gene duplicates to backup
against deleterious human mutations. We find that genes
with close homologs are significantly less likely to harbor
known disease mutations compared to genes with remote
homologs. In addition, close duplicates affect the pheno-
typic consequences of deleterious mutations by making a
decrease in life expectancy less likely. Similarity of
expression profiles across tissues increases the likelihood
of functional compensation by homologs. Taken together,
our analysis demonstrates that functional compensation
by close duplicates plays an important role in human
genetic disease.
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genomes (see Text S1, Supporting Information). The analysis
showed that singleton disease genes are as likely to have duplicate
orthologs as all human singleton genes (9.2% of 338 disease
singletons and 8.5% of 5657 all human singletons, x
2-test P=0.5.
See Figure S3, Supporting Information). Therefore, human
disease genes are as likely to retain duplicates in evolution as all
human genes.
Phenotypic consequences of mutations
The sequence identity between duplicates influences the
phenotypic consequences of gene deletions in yeast [4]. As the
sequence identity decreases, null mutations with weak growth
phenotypes become less likely and mutations with strong growth
phenotypes become more likely. Inspired by this analysis, we
decided to investigate if duplicates also affect phenotypic
consequences of human disease mutations. For that purpose we
used the collection of human disease genes with manually curated
phenotypes [15]. While we did not detect a significant correlation
between the presence of close duplicates and the age of onset, the
population frequency, or the mode of inheritance, we found a
significant correlation between the sequence identity to the closest
duplicate and the reduction in life expectancy (Spearman’s rank
correlation rS=20.21, P=2*10
26, x
2-test, P=2*10
24 see
Figure 3 and Methods). Consequently, the functional compensa-
tion by close duplicates may protect against ‘‘mild’’, ‘‘moderate’’,
and ‘‘severe’’ decline in life expectancy.
Several known examples illustrate this interesting result.
Mutations in red-sensitive opsin gene cause partial colorblindness
(OMIM#303900). Nevertheless, the life expectancy is not
seriously affected due to the presence of the green-sensitive opsin
gene (close homolog of the red-sensitive gene). Another example
involves several homologous iso-enzymes of the human glycogen
phosphorylase; the three iso-enzymes are primarily active in
muscle, liver, and brain. Although defects in the muscle and liver
forms cause glycogen storage disease V (MIM#232600) and VI
(MIM#232700) respectively, neither of the defects reduces life
expectancy.
The effect of expression profile similarities
Because gene duplicates often have different patterns of
expression [25,31,32], it is likely that the functional compensation
depends not only on the sequence similarity, but also on the
similarity of their expression profiles across human tissues. We
decided to test this hypothesis using the comprehensive expression
dataset by Su et al. [33], which includes expression of 44775
human transcripts in 79 tissues.
Initially, we used the absolute values of gene expression in
different tissues to calculate the relative expression difference
between every gene and its closest sequence homolog. The relative
expression difference was defined as (Exp(Gene)2Exp(Paralog)/
(1/2*((Exp(Gene)+Exp(Paralog)). Using this measure we did not
find any significant differences between disease and all genes
(P=0.1). It is likely that each gene is expressed primarily in a small
number of tissues and the simple averaging of expression values
across all tissues will not be informative. Therefore, in order to
better reflect the observed expression patterns, we considered a
gene to be expressed in a tissue if at least one of the gene
Figure 1. The relationship between the sequence identity of the closest homolog and the conditional probability of a disease gene,
P(disease|sequence_identity_of_closest_homolog). Genes with close paralogs are less likely to harbor disease mutations. For display purposes,
we assumed that 20% of all human genes harbor disease mutations (see Methods). The sets of all human genes used for the calculations are A)
Ensembl and B) Swiss-Prot.
doi:10.1371/journal.pgen.1000014.g001
Figure 2. The relationship between the sequence identity of
the closest homolog and the ratio of non-synonymous to
synonymous human SNPs per site (Ka/Ks). The Ka/Ks ratio was
averaged for genes within each sequence identity bin. The ratio is
shown for all (black) and only for validated (red) SNPs from the dbSNP
database [24]. Above 60% sequence identity, the Ka/Ks ratio increases
monotonically as the homolog sequence identity increases.
doi:10.1371/journal.pgen.1000014.g002
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in the tissue by Su et al. [33]. We defined Similarity of Tissue
Expression (STE) for a gene pair as the ratio of the number of
tissues where the two genes are both expressed to the number of
tissues where at least one of the genes is expressed; STE is
essentially the Jaccard’s coefficient of similarity for binary
expression patterns. The STE value of one would indicate
complete overlap between expression profiles, while values close
to zero would indicate poor overlap. Since expression profile
similarity and sequence similarity of duplicates tend to be
correlated [25,31,32], we demonstrated (see Figure 4 and Table
S5, Supporting Information) that the STE values are consistently
lower for disease gene pairs in different sequence bins; the
differences are significant for sequence identity bins from 30% to
80%. We also performed the likelihood ratio test to show that the
similarity in tissue expression influences the probability of being a
disease gene independently of the sequence identity to the closest
homolog (likelihood ratio test x
2=4.0, P,0.05, see Methods).
Conclusions
Our analysis clearly demonstrates that gene duplicates affect the
phenotypic consequences of deleterious human mutations. Several
studies suggested possible mechanisms of functional back-up by
duplicates [4,9,10,34]. It is likely that similar mechanisms also play
a role in human genetic diseases. In some cases duplicates might
Table 1. The GO slim categories which show statistically significant functional compensation by duplicates.
GO ID Description Mean sequence identity of the closest paralog p-value*
Disease genes All genes
Molecular function
0016491 Oxidoreductase activity 47.7% 55.4% 2*10
23
0005488 Binding 53.1% 56.2% 3*10
23
0009055 Electron carrier activity 35.0% 56.4% 3*10
23
0005198 Structural molecule activity 59.9% 69.5% 8*10
23
0003824 Catalytic activity 53.6% 56.8% 1*10
22
Biological process
0050896 Response to stimulus 48.5% 57.3% 7*10
26
0008152 Metabolic process 52.5% 57.4% 1*10
24
0009987 Cellular process 53.0% 57.1% 1*10
24
0006118 Electron transport 45.3% 55.2% 4*10
23
0009058 Biosynthetic process 54.2% 62.2% 7*10
23
*One-sided nonparametric Wilcoxon’s test. A p-value,=1*10
22 corresponds to a total false discovery rate of 5%.
doi:10.1371/journal.pgen.1000014.t001
Figure 3. Influence of the close duplicates on disease
phenotypes. The phenotypic disease data (reduction in life expec-
tancy) were obtained from the study by Jimenez-Sanchez et al. [15]. For
display purposes, we show the proportion of genes with close
duplicates (sequence identity to the closest paralog .=60%) in each
phenotype bin. The proportion of genes with close duplicates
decreases with the reduction in life expectancy.
doi:10.1371/journal.pgen.1000014.g003
Figure 4. The Similarity of Tissue Expression (STE) increases
the likelihood of functional compensation. The STE value
(Jaccard’s coefficient of similarity for gene expression patterns) reflects
the similarity of expression between duplicates across tissues. The
average STE was calculated for gene pairs within each sequence
identity bin. The average STE is consistently lower for disease genes
(black) compared to all genes (red) (see also Table 5S, Supporting
Information).
doi:10.1371/journal.pgen.1000014.g004
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partially carrying the metabolic flux of the mutated gene [25]. In
other cases, genes with close duplicates may have smaller
functional loads compared to singletons, i.e. genes with duplicates
may be essential in a smaller number of environmental conditions
[7]. As a result, a disease phenotype is less likely to be observed.
We take the view that both of these cases represent functional
compensation, although it may be called active compensation in
the first case and passive compensation in the second.
In our view, the probabilistic approach used in our paper to
investigate the likelihood of disease mutations given the sequence
identity of the closest homolog can be applied for identification
and prioritization of medically relevant mutations. Such prioriti-
zation approaches are necessary as large collections of human
genetic variation, such as mutations associated with various
cancers [35,36] and common human polymorphisms [37], are
being generated at an accelerated rate. A probabilistic scheme,
similar to the one used in our paper, can be directly applied as a
prior in search for causative mutations; the information about
homolog expression profiles can be also considered. The
development of such probabilistic prioritization schemes is beyond
the scope of this paper. Nevertheless, the fact that genes with 70–
100% sequence identity homologs are about 2–3 times less likely to
harbor disease mutations, and a significant fraction of such genes
in the human genome, suggest that duplicate homology informa-
tion may be important for the prioritization of medically relevant
mutations.
The collections of disease genes used in our work are
incomplete and significantly biased towards Mendelian diseases
[15]. When large and reliable datasets of genes responsible for
complex diseases become available it will be interesting to
investigate whether fundamental differences exist between
functional compensation for Mendelian and multi-factorial
diseases. In future studies, it will be also important to investigate
robustness to deleterious human mutations achieved through
various network effects [3,9]. Such studies will bring the
important biological concept of robustness into the realm of
human genetics.
Methods
Three sets of human disease genes were used in our study. We
obtained a list of 1003 human genes (1006 Swiss-Prot entries) with
disease non-synonymous mutations from the Swiss-Prot database
[14] (July 2005; http://expasy.org/cgi-bin/lists?humsavar.txt).
The list of 881 human disease genes (923 OMIM entries) with
annotated phenotypes was taken from the study by Jimenez-
Sanchez et al. [15]. We also considered another disease set
consisting of genes annotated as ‘‘disease’’, but neither as
‘‘susceptibility’’ nor as ‘‘non-disease’’ in the OMIM Morbid
Map [13]. This set included 1609 genes (2239 MIM entries). Two
sets of all human genes were used based on the Ensembl [16] and
Swiss-Prot databases. The longest protein isoform of every human
gene was obtained from the Ensembl human genome build 35. We
only retained genes annotated as ‘‘pep:known’’ or ‘‘pep:CCDS’’
(representing genes mapped to human-specific entries of Swiss-
Prot, RefSeq, SPTrEMBL or CCDS). In total 20,262 genes were
included. The other all- human gene set consisted of 12,211
protein sequences from the Swiss-Prot database. All-against-all
BLASTP searches were performed using standard parameters
[17]. Sequence homologs were identified as non-self hits with E-
value ,=0.001 that could be aligned over more than 80% of both
the query length and the length of identified sequence.
Throughout the manuscript the term ‘‘singleton human genes’’
is used to describe the genes without any sequence homologs
which can be identified the BLASTP searches.
We obtained H. sapiens to D. rerio, H. sapiens to G. gallus, and H.
sapiens to M. musculus orthology information as well as paralogous
relationships within D. rerio, G. gallus, and M. musculus from the
Ensembl database [27]. Ka and Ka/Ks values of all 1:1 human-
mouse orthologous pairs were calculated using the PAML package
and obtained directly from the Ensembl database [27].
The sets of synonymous and non-synonymous human SNPs
were obtained from the dbSNP database [24]. These included
87920 SNPs corresponding to 14825 human genes. For each bin
of homolog sequence identity, the Ka/Ks ratio was calculated.
The proportion of non-synonymous sites (0.717) was calculated
from simulation; for each nucleotide in the protein coding region a
random transition or transversion mutation was performed at the
ratio of 0.6/0.4, according to the published estimates in mammals
[38,39,40,41].
We used manually curated phenotypes from the study by
Jimenez-Sanchez et al. [15] to calculated Spearman’s rank
correlation between reduction in life expectancy (ordinal data:
none, mild, moderate, and severe) and sequence identity to the
closest homolog.
The functional categories of human genes used in our study
were based on the annotation by GOA [42]; 53 of GO slims for
GOA (http://www.geneontology.org/GO_slims/goslim_goa.obo)
were considered and Benjamin-Hochberg’s algorithm was applied
for multiple hypothesis correction.
The gene expression profiles in 79 human tissues were obtained
from the study by Su et al. [33]. We eliminated probe sets with
cross hybridization effects (as identified by Su et al.). In total, we
considered expression profiles for 15097 human genes. The
expression value of gene G at tissue T was set to 1 if at least one of
gene G’s transcripts was detected as ‘‘Present call’’ in tissue T
based on the Affymetrix detection algorithm (provided by Su et al.
[33]). Similarity of Tissue Expression (STE) of a gene pair was
defined as the Jaccard’s coefficient of the binary expression profiles
of the two genes, that is, the ratio of the number of tissues where
the two genes are both expressed to the number of tissues where at
least one of the genes is expressed. We performed the likelihood
ratio test to investigate whether the similarity in tissue expression
influences the probability of being a disease gene independently of
the sequence identity to the closest homolog. The logistic
regression was used to model the probability of being a disease
gene using the expression and sequence similarities. In the null
hypothesis the disease gene probability is determined only by
sequence identity of the closest homolog; in the alternative
hypothesis the probability is determined by sequence identity and
tissue expression similarity of the closest homolog.
The probabilities shown in Figure 1 represent conditional
probabilities. Specifically, the conditional probability P(disease|
seq_id_homolog) that a gene is associated with a genetic disease
given that it has a closest homolog with a certain sequence identity,
was calculated according to the equation:
P diseasejseq id hom olog ðÞ
~
P seq id hom ologjdisease ðÞ
P seq id hom olog ðÞ
P disease ðÞ
where P(seq_id_homolog | disease) is the probability that the
closest homolog of a disease gene has a certain sequence identity,
P(seq_id_homolog) is the probability that a randomly selected
human gene (disease or non-disease) has a closest homolog with a
certain sequence identity, and P(disease) is the probability that a
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Importantly, because P(disease) is currently unknown (as we know
only a fraction of all disease genes), we estimate P(disease |
seq_id_homolog) up to a constant by assuming certain P(disease)
value. For display purposes, we assumed P(disease)=0.2 in
Figure 1.
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